New immune therapy targets tumor-associated environment: From bone marrow to tumor site

Cellular and Molecular Immunology

Volumn 9, Issue 1, 2012, Pages 1-2

  Fu, Yang Xin ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; MYELOID DIFFERENTIATION FACTOR 88; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHOTRANSFERASE INHIBITOR; STROMAL CELL DERIVED FACTOR 1; TOLL LIKE RECEPTOR 4; TUMOR ANTIGEN; TUMOR PROTEIN; VIRUS VECTOR;

ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE T CELL TRANSFER THERAPY; ANTIGEN EXPRESSION; APOPTOSIS; BONE MARROW; BONE MARROW METASTASIS; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CARCINOGENESIS; CELL KILLING; CELL MIGRATION; DENDRITIC CELL; EDITORIAL; GENETIC ASSOCIATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOGENETICS; IMMUNOSUPPRESSIVE TREATMENT; INTRACELLULAR SIGNALING; MELANOMA; MOLECULAR MECHANICS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR LOCALIZATION; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; VIRUS EXPRESSION;

ANIMALS; BONE MARROW; HUMANS; IMMUNOTHERAPY; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84855371207     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2011.54     Document Type: Editorial

References (21)

1. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996; 183: 725-729. (Pubitemid 26113944)
2. Yu P, Rowley DA, Fu YX, Schreiber H. The role of stroma in immune recognition and destruction of well-established solid tumors. Curr Opin Immunol 2006; 18: 226-231. (Pubitemid 43327307)
3. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-915. (Pubitemid 39273730)
4. 1 T cells. J Exp Med 2003; 198: 569-580. (Pubitemid 37040391)
5. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2003; 298: 850-854.
6. Zhou P, Fang X, McNally BA, Yu P, Zhu M, Fu YX et al. Targeting lymphotoxin-mediated negative selection to prevent prostate cancer in mice with genetic predisposition. Proc Natl Acad Sci USA 2009; 106: 17134-17149.
7. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002; 2: 227-238. (Pubitemid 37323223)
8. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263-274. (Pubitemid 40488632)
9. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295-307.
10. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-949. (Pubitemid 39273735)
11. 1 cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 2005; 201: 779-791. (Pubitemid 40395122)
12. 1 regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res 2004; 64: 8451-8455. (Pubitemid 39491786)
13. Zhao E, Wang L, Dai J, Kryczek I, Wei S, Vatan L et al. Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer. OncoImmunology 2011; in press.
14. Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010; 18: 160-170.
15. Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci USA 2011; 108: 7142-7147.
16. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011; 17: 1094-1100.
17. 1 T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 2010; 18: 485-498.
18. 1 T cells: changing strategies for cancer treatment. Blood 2009; 114: 589-595.
19. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-1059. (Pubitemid 47517504)
20. Lee Y, Chin RK, Christiansen P, Sun Y, Tumanov AV, Wang J et al. Recruitment and activation of naive T cells in the islets by lymphotoxin beta receptor-dependent tertiary lymphoid structure. Immunity 2006; 25: 499-509. (Pubitemid 44376723)
21. Yu P, Lee Y, Liu W, Chin RK, Wang J, Wang Y, Schietinger A et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 2004; 5: 141-149. (Pubitemid 38208355)